POSTERIOR SUB-TENON'S Avastin

POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00567372

Enrollment

Registered

2007-12-04

Start date

2008-06-30

Completion date

2009-06-30

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Diabetic Macular Edema

Keywords

Diffuse diabetic macular edema, sub-tenon, Bevacizumab

Brief summary

Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema

Interventions

DRUGbevacizumab (Sub-tenon´s injection)

a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 90 Years

Healthy volunteers

Inclusion criteria

Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat thickness ≥250 μ BCVA ≥ 20/400 Without any treatment

Design outcomes

Primary

Measure	Time frame
macular volume	baseline, 3,6 and 12 weeks

Secondary

Measure	Time frame
macular thickness	baseline,3,6 and 12 weeks
best corrected visual acuity	baseline, 3,6 and 12 weeks

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026